104 related articles for article (PubMed ID: 38951877)
1. Incretin-based therapy and the risk of diabetic foot ulcers and related events.
Werkman NCC; Driessen JHM; Klungel OH; Schaper NS; Souverein PC; Stehouwer CDA; Nielen JTH
Diabetes Obes Metab; 2024 Jul; ():. PubMed ID: 38951877
[TBL] [Abstract][Full Text] [Related]
2. The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study.
Werkman NCC; Driessen JHM; Stehouwer CDA; Vestergaard P; Schaper NC; van den Bergh JP; Nielen JTH
Cardiovasc Diabetol; 2023 Jun; 22(1):160. PubMed ID: 37386427
[TBL] [Abstract][Full Text] [Related]
3. Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors
Lu Y; Guo C
Ther Adv Drug Saf; 2023; 14():20420986231178126. PubMed ID: 37332886
[TBL] [Abstract][Full Text] [Related]
4. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U
Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
Pasternak B; Wintzell V; Hviid A; Eliasson B; Gudbjörnsdottir S; Jonasson C; Hveem K; Svanström H; Melbye M; Ueda P
BMJ; 2024 Apr; 385():e078225. PubMed ID: 38683947
[TBL] [Abstract][Full Text] [Related]
6. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study.
Patorno E; Everett BM; Goldfine AB; Glynn RJ; Liu J; Gopalakrishnan C; Kim SC
Diabetes Obes Metab; 2016 Aug; 18(8):755-65. PubMed ID: 27003762
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared With Incretin-Based Therapy in Patients With Diabetic Foot Disease: A Nationwide Population-Based Study.
Lin YH; Lin CH; Lin YC; Huang YY; Tai AS; Fu SC; Lin SH
Endocr Pract; 2024 May; 30(5):424-430. PubMed ID: 38325629
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis.
McCormick TA; Kramer J; Liles EG; Amos Q; Martin JP; Adams JL
BMJ Open Diabetes Res Care; 2024 May; 12(3):. PubMed ID: 38719507
[TBL] [Abstract][Full Text] [Related]
9. Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.
Driessen JH; Henry RM; van Onzenoort HA; Lalmohamed A; Burden AM; Prieto-Alhambra D; Neef C; Leufkens HG; de Vries F
Calcif Tissue Int; 2015 Aug; 97(2):104-12. PubMed ID: 25894068
[TBL] [Abstract][Full Text] [Related]
10. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B
Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ
Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492
[TBL] [Abstract][Full Text] [Related]
12. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
Drake T; Landsteiner A; Langsetmo L; MacDonald R; Anthony M; Kalinowski C; Ullman K; Billington CJ; Kaka A; Sultan S; Wilt TJ
Ann Intern Med; 2024 May; 177(5):618-632. PubMed ID: 38639549
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
14. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
15. [The incretin effect and type 2 diabetes].
Quintanilla-García C; Zúñiga-Guajardo S
Rev Med Inst Mex Seguro Soc; 2010; 48(5):509-20. PubMed ID: 21205499
[TBL] [Abstract][Full Text] [Related]
16. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
[TBL] [Abstract][Full Text] [Related]
17. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture.
Driessen JH; van Onzenoort HA; Henry RM; Lalmohamed A; van den Bergh JP; Neef C; Leufkens HG; de Vries F
Bone; 2014 Nov; 68():124-30. PubMed ID: 25093264
[TBL] [Abstract][Full Text] [Related]
18. Prediction of outcomes in subjects with type 2 diabetes and diabetic foot ulcers in Catalonian primary care centers: a multicenter observational study.
Bundó M; Vlacho B; Llussà J; Bobé I; Aivar M; Ciria C; Martínez-Sánchez A; Real J; Mata-Cases M; Cos X; Dòria M; Viade J; Franch-Nadal J; Mauricio D
J Foot Ankle Res; 2023 Feb; 16(1):8. PubMed ID: 36849888
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.
Gamble JM; Thomas JM; Twells LK; Midodzi WK; Majumdar SR
Medicine (Baltimore); 2016 Jun; 95(26):e3995. PubMed ID: 27368005
[TBL] [Abstract][Full Text] [Related]
20. Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis.
Du Y; Bai L; Fan B; Ding H; Ding H; Hou L; Ma H; Xing N; Wang F
Prim Care Diabetes; 2022 Feb; 16(1):156-161. PubMed ID: 34930687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
